Medical Oncology

, Volume 23, Issue 1, pp 91–104

Advanced colon cancer

Antiprogressive immunotherapy using an autologous hemoderivative
  • Eduardo Lasalvia-Prisco
  • Emilio Garcia-Giralt
  • Silvia Cucchi
  • Jesús Vázquez
  • Eduardo Lasalvia-Galante
  • Wilson Golomar
  • Joshemaria Larrañaga
Original Article

Abstract

Introduction

Advanced colon cancer patients, acquired-chemotherapy resistant and in progression, are therapeutically terminal. We tested a recently described medical procedure using a thermostable autologous hemoderivative purported to inhibit tumor growth possibly through an immunological mechanism of action.

Patients and Methods

Metastatic colon cancer patients chemotherapy-resistant, high CEA plasma levels, in progression, were 2-group randomized. Group 1 received the test procedure and Group 2 adequate control measures. During an 8-mo follow-up period (n=101), tumor growth, number of cases attaining clinical nonprogressive status, and mortality were assessed monthly. Immunological effect was assessed by delayed-type hypersensitivity test and lymphocyte proliferation assay. Responding-tumors histopathologies were studied.

Results and Discussion

In a significant number of cases, the test procedure promoted inhibition of tumor growth, nonprogressive disease status, and lower cumulative mortality. These clinical results were associated with polyvalent immunization against several tested antigens: the hemoderivative used for treatment, the blood tumor markers, and the regulatory lymphocyte population (CD4+CD25+). Interference with this regulatory activity could explain the selective autoimmunity suggested by the histopathology findings in responding tumors.

Conclusion

The autologous hemoderivative tested is antigenically polyvalent and promotes a polytargeted immune response associated with a tumor antiprogressive effect, consequently, acting as an autologous hemoderivative cancer vaccine.

Key words

Autologous hemoderivative colon cancer vaccine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lasalvia E, et al. Autologous induction of tumoral fibrogenesis. Neoplasia 1995; 12:5–10.Google Scholar
  2. 2.
    Lasalvia E, Cucchi S, Carlevaro T, Vasquez J, Riotorio R, Fierro L. Anti-metastatic effect of a blood fraction from cancer patients (Meeting abstract). Proceedings 31st Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, USA, 1995, Abstract No. 730Google Scholar
  3. 3.
    Lasalvia-Prisco E, et al. Antitumoral effect of a vaccination procedure with an autologous hemoderivative. Cancer Biol Ther 2003; 2:155–160.PubMedGoogle Scholar
  4. 4.
    Berd D, Mastrangelo MJ, Engstrong P, Maguire H. Augmentation of the human immune response by cyclophosphamide. Cancer Res 1982; 42:4862–4866.PubMedGoogle Scholar
  5. 5.
    Leong SP, et al. Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J Immunother 1999; 22:166.PubMedCrossRefGoogle Scholar
  6. 6.
    Oken MM, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649–655.PubMedGoogle Scholar
  7. 7.
    Therasse P, et al. New guideline to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment Cancer, National Cancer Institute of the United States National Cancer Institute of Canada. J Nat Cancer Inst 2000; 92:205–216.PubMedCrossRefGoogle Scholar
  8. 8.
    World Medical Association Declaration of Helsinki: Recommendations guiding medical doctors in biomedical research involving human subjects. Adopted by the 18th World Medical Assembly, Helsinki, Finland, 1964 and as revised in Tokyo, 1975, in Venice, 1983, in Hong Kong, 1989. Version with changes of 1997.Google Scholar
  9. 9.
    PDQ (Physician Data Query) National Cancer Institute, comprehensive cancer database.Google Scholar
  10. 10.
    Ozer H, et al. 2000 update of recommendations for the use of heamatopoietic colony-stimulating factors: evidencebased, clinical practice guidelines. J Clin Oncol. 2000; 18:3558–3585.PubMedGoogle Scholar
  11. 11.
    Lasalvia-Prisco E, Garcia-Giralt E, Cucchi S, Vazquez J. Lasalvia-Galante E, Golomar W. Colorectal cancer: comparative effects of an autologous hemoderivative vaccine with a CEA vaccine and/or an autologous [CD4+CD25+] vaccine. Proceedings 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, USA, 2005, Abstract No. 2596.Google Scholar
  12. 12.
    Wan Fai Ng, et al. Human CD4+CD25+ cells: a naturally occurring population of regulatory T cells. Blood 2001; 98:2736–2744.CrossRefGoogle Scholar
  13. 13.
    Gauthier LR, et al. Detection of circulating carcinoma cells by telomerase activity. Br J Cancer 2001; 84:631–635.PubMedCrossRefGoogle Scholar
  14. 14.
    National Cancer Institute, US: Common terminology criteria for adverse events v3.0 (CTCAE).Google Scholar
  15. 15.
    Saetang T, Suttijitpaisal P, Ratanabanangkoon K. Preparations of toxic components from Naja kaouthia venom by selective heat denaturation. J Nat Toxins 1998; 7:37–44.PubMedGoogle Scholar
  16. 16.
    Bruster HTH, Kuntz BME, Scheja JW. Autovaccination plus heat-inactivated autologous plasma in AIDS Patients. Lancet 1988; 1:1284–1285.PubMedCrossRefGoogle Scholar
  17. 17.
    Petrunin DD, Lopukin Iu M, Molodenkov MN, Olifirenko GA. Immunochemical identification of thermostable alphaglycoprotein in blood sera in various immune system diseases. Biull Eksp Biol Med 1982; 93:66–68.PubMedCrossRefGoogle Scholar
  18. 18.
    Snegotska O. [Autovaccines for the treatment of cancer]. Folia Clin Int (Barc. Spain) 1965; 15:303–308.Google Scholar
  19. 19.
    Liyanage UK, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169:2756–2761.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2006

Authors and Affiliations

  • Eduardo Lasalvia-Prisco
    • 4
    • 3
  • Emilio Garcia-Giralt
    • 1
  • Silvia Cucchi
    • 2
  • Jesús Vázquez
    • 2
    • 3
  • Eduardo Lasalvia-Galante
    • 2
  • Wilson Golomar
    • 2
    • 3
  • Joshemaria Larrañaga
    • 2
    • 3
  1. 1.Centre De Cancerologie HartmannNeuilly Sur SeineFrance
  2. 2.Department of Advanced Medical TreatmentsMontevideoUruguay
  3. 3.National Institute of OncologyMontevideoUruguay
  4. 4.Research & Development DepartmentPharmaBlood IncNorth Miami BeachUSA

Personalised recommendations